Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of brolucizumab versus aflibercept for diabetic macular edema
MOH_2018-06-14_002281Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab and aflibercept in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Started May 2018; status: completed.
02
Drugs
brolucizumabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2018-06-14_002281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-14_002281.